This phase 1b, Open-Label Study will assess the safety, efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).~Patients who meet the criteria for the study CORT-118335-861 will be enrolled on Day 1 into 1 of 6 cohorts and receive:~Cohort 1 - a daily dose of 150 mg of miricorilant over 24 weeks~Cohort 2 - a daily dose of 150 mg of miricorilant over 12 weeks~Cohort 3 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday, Wednesday and Friday~Cohort 4 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday and Friday~Cohort 5 - 100 mg of miricorilant over 12 weeks every Monday, Wednesday and Friday~Cohort 6 - 100 mg of miricorilant over 12 weeks every Monday and Friday~Cohort 7 - a daily dose of 50 mg of miricorilant over 12 weeks.~Cohort 8 - a daily dose of 100 mg of miricorilant over 12 weeks.~Cohort 9 - a daily dose of 30 mg of miricorilant over 12 weeks.~Cohort 10 - a once weekly dose of 200 mg of miricorilant over 12 weeks.
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)